Jiangsu Sihuan Bioengineering Co., Ltd (SHE:000518)
3.160
+0.020 (0.64%)
Nov 5, 2026, 3:04 PM CST
SHE:000518 Revenue
Jiangsu Sihuan Bioengineering had revenue of 123.11M CNY in the quarter ending September 30, 2026, with 9.45% growth. This brings the company's total for the last twelve months to 283.86M, down -16.97% year-over-year. In the year 2025, Jiangsu Sihuan Bioengineering had annual revenue of 344.38M with 69.22% growth. That makes Jiangsu Sihuan Bioengineering the 29,115th largest company in the world by revenue and 4,896th in China.
Revenue (ttm)
283.86M
Revenue Growth
-16.97%
P/S Ratio
11.46
Revenue / Employee
1.22M
Employees
232
Market Cap
3.25B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:000518 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 344.38M | 140.87M | 69.22% |
| Dec 31, 2024 | 203.52M | -31.90M | -13.55% |
| Dec 31, 2023 | 235.42M | -34.73M | -12.86% |
| Jan 1, 2023 | 270.15M | -80.81M | -23.03% |
| Jan 1, 2022 | 350.96M | -154.44M | -30.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.88B |
| Wuhan Hvsen Biotechnology | 1.71B |
| Hefei Lifeon Pharmaceutical | 1.46B |
| Qingdao Vland Biotech INC. | 1.45B |
| Kexing Biopharm | 1.30B |
| Pulike Biological Engineering | 1.00B |
| Shanghai Model Organisms Center | 486.90M |
| Beijing Scitop Bio-tech | 365.18M |